German contract manufacturer Rentschler Biotechnologie has signed a manufacturing agreement with Finland-based drug discovery firm Faron Pharmaceuticals to supply FP-1201 (Traumakine).
The active pharmaceutical ingredient of FP-1201 is recombinant human interferon beta-1a (IFN-beta 1a), which was first produced by Rentschler in the late 1980s. According to the terms of the agreement, Rentschler will become sole manufacturer of IFN-beta 1a for Faron and also manufacture Faron’s proprietary bulk drug product.
Traumakine prevents vascular leakage in patients with acute lung injuries (ALI) and its more severe form ARDS. It is currently in a Phase I/II study in the UK.
The active pharmaceutical ingredient of FP-1201 is recombinant human interferon beta-1a (IFN-beta 1a), which was first produced by Rentschler in the late 1980s. According to the terms of the agreement, Rentschler will become sole manufacturer of IFN-beta 1a for Faron and also manufacture Faron’s proprietary bulk drug product.
Traumakine prevents vascular leakage in patients with acute lung injuries (ALI) and its more severe form ARDS. It is currently in a Phase I/II study in the UK.
No comments:
Post a Comment